Abstract
Reinvigoration of antitumor immunity remains an unmet challenge. Our retrospective analyses revealed that cancer patients who took antihistamines during immunotherapy treatment had significantly improved survival. We uncovered that histamine and histamine receptor H1 (HRH1) are frequently increased in the tumor microenvironment and induce T cell dysfunction. Mechanistically, HRH1-activated macrophages polarize toward an M2-like immunosuppressive phenotype with increased expression of the immune checkpoint VISTA, rendering T cells dysfunctional. HRH1 knockout or antihistamine treatment reverted macrophage immunosuppression, revitalized T cell cytotoxic function, and restored immunotherapy response. Allergy, via the histamine-HRH1 axis, facilitated tumor growth and induced immunotherapy resistance in mice and humans. Importantly, cancer patients with low plasma histamine levels had a more than tripled objective response rate to anti-PD-1 treatment compared with patients with high plasma histamine. Altogether, pre-existing allergy or high histamine levels in cancer patients can dampen immunotherapy responses and warrant prospectively exploring antihistamines as adjuvant agents for combinatorial immunotherapy.
Original language | English (US) |
---|---|
Pages (from-to) | 36-52.e9 |
Journal | Cancer cell |
Volume | 40 |
Issue number | 1 |
DOIs | |
State | Published - Jan 10 2022 |
Keywords
- HRH1
- T cell dysfunction
- allergy
- antihistamine
- cancer immunotherapy
- histamine
- immune evasion
- macrophage
ASJC Scopus subject areas
- Oncology
- Cell Biology
- Cancer Research
MD Anderson CCSG core facilities
- Advanced Technology Genomics Core
- Research Animal Support Facility
- Biostatistics Resource Group
- Tissue Biospecimen and Pathology Resource
- Functional Genomics Core
- Flow Cytometry and Cellular Imaging Facility